- Companies
- BaroPharm
BaroPharm Valuation Multiples
BaroPharm is valued at $60M as of November 2026. In the last fiscal year, BaroPharm revenue was $130M.
BaroPharm Overview
About BaroPharm
BaroPharm Co operates a healthcare platform business based on IT technology that supports the efficiency of pharmaceutical ordering and management operations in pharmacies. Its key services consist of integrated pharmaceutical ordering, price and inventory comparison, payment and return notifications, and out-of-stock and restock alerts, along with functions such as pharmaceutical information search, education, community features, and management support.
Founded
2009
HQ
Employees
N/A
Website
Financials (Last FY)
Market Cap
$60M
Valuation Multiples
Start free trialBaroPharm Financials
BaroPharm reported last fiscal year revenue of $130M.
In the same fiscal year, BaroPharm generated $24M in gross profit and $5M in net income.
BaroPharm P&L
In the most recent fiscal year, BaroPharm reported revenue of $130M and net income of $5M.
BaroPharm is profitable as of last fiscal year, with gross margin of 19% and net margin of 4%.
Financial data powered by Morningstar, Inc.
BaroPharm Stock Performance
BaroPharm has current market cap of $60M.
BaroPharm's stock price is $5.01.
BaroPharm has an EPS (earnings per share) of $0.44.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $60M | -8.4% | - | - | - | $0.44 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBaroPharm Valuation Multiples
BaroPharm Financial Valuation Multiples
As of November 18, 2026, BaroPharm has market cap of $60M.
BaroPharm has a P/E ratio of 11.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BaroPharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


BaroPharm Margins & Growth Rates
BaroPharm grew revenue by 30% and net profit by 105% in the last fiscal year.
In the most recent fiscal year, BaroPharm reported gross margin of 19% and net margin of 4%.
BaroPharm Margins
BaroPharm Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BaroPharm Competitors
BaroPharm competitors include Vulcan Two Group, Cango, Gear4music, Kamux, CarParts.com, Carma, MARX Biotech, Online Brands Nordic, Marks Electrical Group and Aromatica Co.
Most BaroPharm public comparables operate across Pharmacies, Consumer E-commerce and Vertical E-commerce.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($2M) | - | 1.1x | (31.9x) | 28.4x | |||
| $688M | ($317M) | 0.1x | 0.3x | (0.3x) | (0.9x) | |||
| $252M | $24M | 0.3x | 0.3x | 3.0x | 4.0x | |||
| $964M | $16M | 0.1x | 0.1x | 6.2x | 12.6x | |||
| $548M | ($28M) | 0.1x | 0.2x | (2.8x) | 131.6x | |||
| $77M | ($22M) | 0.7x | 0.5x | (2.3x) | (2.8x) | |||
| $19M | $3M | 3.6x | - | 25.3x | - | |||
| $47M | $2M | 1.2x | 0.9x | 30.2x | 11.4x | |||
This data is available for Pro users. Sign up to see all BaroPharm competitors and their valuation data. Start Free Trial | ||||||||
BaroPharm VC Funding History
Before going public, BaroPharm raised $25M in total equity funding, across 2 rounds.
BaroPharm Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BaroPharm
| When was BaroPharm founded? | BaroPharm was founded in 2009. |
| Where is BaroPharm headquartered? | BaroPharm is headquartered in South Korea. |
| Is BaroPharm publicly listed? | Yes, BaroPharm is a public company listed on Korea Exchange. |
| What is the stock symbol of BaroPharm? | BaroPharm trades under 0153R0 ticker. |
| When did BaroPharm go public? | BaroPharm went public in 2026. |
| Who are competitors of BaroPharm? | BaroPharm main competitors include Vulcan Two Group, Cango, Gear4music, Kamux, CarParts.com, Carma, MARX Biotech, Online Brands Nordic, Marks Electrical Group, Aromatica Co. |
| What is the current market cap of BaroPharm? | BaroPharm's current market cap is $60M. |
| What is the current revenue of BaroPharm? | BaroPharm's last fiscal year revenue is $130M. |
| What is the current revenue growth of BaroPharm? | BaroPharm revenue growth (vs. last FY) is 30%. |
| Is BaroPharm profitable? | No, BaroPharm is not profitable. |
| How many companies BaroPharm has acquired to date? | BaroPharm hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies BaroPharm has invested to date? | BaroPharm hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to BaroPharm
Lists including BaroPharm
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




